87 related articles for article (PubMed ID: 22059804)
41. Skeletal health in patients with differentiated thyroid carcinoma.
Cellini M; Rotondi M; Tanda ML; Piantanida E; Chiovato L; Beck-Peccoz P; Lania A; Mazziotti G
J Endocrinol Invest; 2021 Mar; 44(3):431-442. PubMed ID: 32696339
[TBL] [Abstract][Full Text] [Related]
42. The clinical efficacy of Apatinib plus Ba Zhen granules in the treatment of advanced unresectable differentiated thyroid cancer and their influence on immune factors.
Bai Y; Jin J; Liu Y; Zhang B; Li J
Pak J Pharm Sci; 2023 May; 36(3(Special)):935-939. PubMed ID: 37587701
[TBL] [Abstract][Full Text] [Related]
43. Health Anxiety and Its Relationship to Thyroid-Hormone-Suppression Therapy in Patients with Differentiated Thyroid Cancer.
Zoltek M; Andersson TM; Axelsson E; Hedman C; Ihre Lundgren C
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625954
[TBL] [Abstract][Full Text] [Related]
44. Treatment related morbidity in differentiated thyroid cancer-a survey of clinicians.
Edafe O; Wadsley J; Harrison BJ; Balasubramanian SP
Thyroid Res; 2014 Mar; 7(1):3. PubMed ID: 24618295
[TBL] [Abstract][Full Text] [Related]
45. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
46. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
47. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
48. Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy.
Gigliotti BJ; Jasim S
Endocrine; 2024 Feb; 83(2):251-258. PubMed ID: 37824045
[TBL] [Abstract][Full Text] [Related]
49. Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis.
Giovanella L; Garo ML; Campenní A; Petranović Ovčariček P; Görges R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173976
[TBL] [Abstract][Full Text] [Related]
50. Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy.
Ran B; Wei F; Gong J; Xu H
Front Endocrinol (Lausanne); 2022; 13():1004962. PubMed ID: 36313757
[TBL] [Abstract][Full Text] [Related]
51. Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer.
Stramazzo I; Capriello S; Antonelli A; Fallahi P; Centanni M; Virili C
Hormones (Athens); 2022 Dec; 21(4):537-543. PubMed ID: 35655116
[TBL] [Abstract][Full Text] [Related]
52. Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9-12 months after treatment.
Nordell F; Hallal G; Asp P; Almquist M
BJS Open; 2021 Nov; 5(6):. PubMed ID: 34882764
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy.
Wang Z; Angell TE; Sun W; Qin Y; He L; Dong W; Zhang D; Zhang T; Shao L; Lv C; Zhang P; Guan H; Zhang H
Ann Transl Med; 2020 Oct; 8(19):1238. PubMed ID: 33178770
[TBL] [Abstract][Full Text] [Related]
54. Thyroid hormone therapy in differentiated thyroid cancer.
Grani G; Ramundo V; Verrienti A; Sponziello M; Durante C
Endocrine; 2019 Oct; 66(1):43-50. PubMed ID: 31617165
[TBL] [Abstract][Full Text] [Related]
55. THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS.
Prpić M; Franceschi M; Romić M; Jukić T; Kusić Z
Acta Clin Croat; 2018 Sep; 57(3):518-527. PubMed ID: 31168186
[TBL] [Abstract][Full Text] [Related]
56. Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.
Klubo-Gwiezdzinska J; Auh S; Gershengorn M; Daley B; Bikas A; Burman K; Wartofsky L; Urken M; Dewey E; Smallridge R; Chindris AM; Kebebew E
JAMA Netw Open; 2019 Feb; 2(2):e187754. PubMed ID: 30707227
[TBL] [Abstract][Full Text] [Related]
57. Thyroid cancer: Balancing benefit and risk in TSH management of DTC.
Verburg FA; Luster M
Nat Rev Endocrinol; 2018 Mar; 14(3):136-137. PubMed ID: 29348477
[No Abstract] [Full Text] [Related]
58. Pediatric papillary thyroid cancer: current management challenges.
Verburg FA; Van Santen HM; Luster M
Onco Targets Ther; 2017; 10():165-175. PubMed ID: 28096684
[TBL] [Abstract][Full Text] [Related]
59. Thyroid Hormone Replacement in Patients Following Thyroidectomy for Thyroid Cancer.
Hannoush ZC; Weiss RE
Rambam Maimonides Med J; 2016 Jan; 7(1):. PubMed ID: 26886951
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
